| In partnership with |  |
| & The Motley Fool | Good day, 360! | Here are some of our top movers today. And for all our latest trade ideas, text "RAGE" to 1-(888) 404-5747 (must put the "1" in!). Yesterday's alert closed up over 15% despite all the market jitters. Be the best excited on the Street! | | FOCUS LIST🔎 | SANA - Up over 240% in the pre-market after announcing positive clinical results from Type 1 Diabetes study of Islet cell transplantation without immunosuppression | CURR - Up over 180% in the pre-market after debuting SEAMLESS AI call centre solutions | ABSI - Up over 50% in pre after announcing collaboration and strategic investment with AMD to accelerate the future of AI drug discovery | | *sponsored by The Motley Fool | Fortune Favors The Bold | | Ever wish you could turn back time and invest in Amazon's early days? Well, buckle up because the AI revolution is offering a second chance. | In The Motley Fool's latest report, dive into the world of AI-powered innovation. Discover why experts are calling it "the rocket fuel of AI" and predicting a market cap 41 times larger than Amazon's. | Don't let past regrets hold you back. Take charge of your future and capitalize on the AI wave with The Motley Fool's exclusive report. | Whether it's AI or Amazon, fortune favors the bold. | Don't miss out. Dive into the report today. |
|
| | HOTLIST🔥 | SANA - Up over 240% in the pre-market after announcing positive clinical results from Type 1 Diabetes study of Islet cell transplantation without immunosuppression | Sana Biotechnology Inc. (SANA) is a biotechnology company that focuses on utilizing engineered cells as medicines. | In the after-hours yesterday, the company announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. | Highlights include: | First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression | Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes | Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT) | MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation | Conference Call to be Webcast at 1:30pm PT | Shares of SANA traded up over 240% in the pre-market in reaction to the news. | | The $5.22 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $5.90, $6.10, $7.25 and then the pre-market high at $8.12. Beyond that, $9 and $10 come into play. | Below $5.22, targets to the downside are $4.75, $4.35, $3.80, $2.85, $2.30 and then $2. | | CURR - Up over 180% in the pre-market after debuting SEAMLESS AI call centre solutions | CURRENC Group Inc. (CURR) is a fintech and digital remittance pioneer serving millions of unbanked and underbanked individuals in Southeast Asia and beyond. | In the pre-market this morning, the company announced the launch of its SEAMLESS AI Call Centre Solutions, a suite of AI-powered tools designed to reduce costs, increase efficiency and boost customer satisfaction for banks, insurance companies, telecommunications companies, government agencies, cryptocurrency exchanges and other financial institutions. | SEAMLESS AI Call Centre Solutions features three distinct software products supported by massive data analysis capabilities, enabling financial enterprises to offer their users an unparalleled service experience 24/7. | "Text AI" leverages the familiarity of chat-based interfaces to deliver real-time product Q&As and personalized service follow-ups in a conversational format. | "Voice AI" allows for instant, hands-free interaction with an AI agent, ensuring an intuitive and accessible user journey from simple inquiries to complex, step-by-step guidance for completing transactions or Know Your Customer processes. | Finally, "Avatar AI" adds a human touch to query resolution and task management through 2D or 3D avatars that simulate real-life interactions. These products are available in over 10 languages and are easily embedded into mobile applications, putting an engaging communication channel and seamless experience at global users' fingertips around the clock. | Shares of CURR traded up over 150% in the pre-market in reaction to the news. | | The first target for bulls is pre-market resistance at $4.10, $4.30 and then the pre-market high at $4.56. Beyond that $5 and $5.74 come into play. | Below $4.10, targets to the downside are $3.55, $3.20, $2.83, $2.68, $2.20, $1.85, $1.50 and a gap fill at $1.39. | | In partnership with | |
| Looking for unbiased, fact-based news? Join 1440 today. | | Upgrade your news intake with 1440! Dive into a daily newsletter trusted by millions for its comprehensive, 5-minute snapshot of the world's happenings. We navigate through over 100 sources to bring you fact-based news on politics, business, and culture—minus the bias and absolutely free. | Subscribe to 1440 today. |
|
| | ABSI - Up over 50% in pre after announcing collaboration and strategic investment with AMD to accelerate the future of AI drug discovery | Absci Corporation (ABSI) operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. | In the pre-market this morning, the company announced strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models. | AMD will also make a $20 million investment in Absci, structured as a private investment in public equity (PIPE), underscoring the growing demand for innovative AI applications in drug discovery. | Shares of ABSI traded up over 50% in the pre-market in reaction to the news. | | The $4.42 area acted as resistance in the pre-market and now becomes a level of potential support. | Above it, targets to the upside are $5 and then the pre-market high at $5.15. Beyond that, $5.40, $5.80 and $6.20 come into play. | Below $4.42, targets to the downside are $4, $3.70, $3.50 and then a gap fill at $3.07. | | MARKET NEWS 📰 | | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don't spend any money on these products or services unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
Tidak ada komentar:
Posting Komentar